sellWeak cluster of 310b5-1 plan
Thomas Tu sold $220k of NARI
Chief Medical Officer at Inari Medical, Inc.. 4,000 shares at an average of $55.00, traded Dec 10, 2024, filed Dec 12, 2024.
Warning score
22Value
$220k
4,000 shares
Holdings after
304,036
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +12Trade size$220k at market
- 0Share of holdings soldSold 1.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001127602-24-029276, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 10, 2024 | SOpen-market sale Common Stock10b5-1 | -4,000 | $55.00 | $220k | 304,036 | Dec 12, 2024 |
Related signals
Other insiders at Inari Medical, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Inari Medical, Inc. | William Hoffman director | $12M 200,000 shares | -46% | |
| 31Weak | Inari Medical, Inc. | Andrew Hykes President and CEO | $166k 3,000 shares | -1% | |
| 40Moderate | Inari Medical, Inc. | William Hoffman director | $3.3M 60,000 shares | -12% | |
| 24Weak | Inari Medical, Inc. | Andrew Hykes President and CEO | $152k 3,000 shares | -1% | |
| 33Weak | Inari Medical, Inc. | William Hoffman director | $3.1M 60,000 shares | -11% | |
| 28Weak | Inari Medical, Inc. | William Hoffman director | $2.0M 40,000 shares | -7% | |
| 24Weak | Inari Medical, Inc. | Andrew Hykes President and CEO | $150k 3,000 shares | -1% | |
| 28Weak | Inari Medical, Inc. | William Hoffman director | $1.8M 40,000 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.